Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2022; 28(17): 1768-1780
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1768
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1768
Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
Neil Grey, Radiology-Nuclear Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, United States
Michael Silosky, Bennett B Chin, Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, United States
Christopher H Lieu, Medical Oncology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, United States
Author contributions: Grey N, Silosky M, Lieu CH, and Chin BB all contributed to the writing and editing of the manuscript; all authors have read and approve the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in the content of this review article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bennett B Chin, MD, Professor, Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, 12401 East 17th Avenue, Mail Stop L954A, Aurora, CO 80045, United States. bennett.chin@cuanschutz.edu
Received: October 19, 2021
Peer-review started: October 19, 2021
First decision: December 3, 2021
Revised: January 7, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 7, 2022
Processing time: 192 Days and 4.2 Hours
Peer-review started: October 19, 2021
First decision: December 3, 2021
Revised: January 7, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 7, 2022
Processing time: 192 Days and 4.2 Hours
Core Tip
Core Tip: 68Ga and 64Cu DOTATATE positron emission tomography imaging is the most sensitive and accurate method to identify well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The paired therapeutic radiotracer, 177Lu DOTATATE, delivers targeted radiation which can prolong progression free survival. This is now established as the therapeutic best standard of care for patients with progressive, metastatic, or unresectable well-differentiated somatostatin receptors positive GEP-NETs. Ongoing investigations continue to expand the potential indications for DOTATATE theranostics. Additional novel ligands are also currently being developed for targeted imaging and therapy of GEP-NETs.